Collegium Pharmaceutical, Inc. (COLL) — Fair Value Analysis

Base-case fair value (P50): $40.58 · Current price: $33.27 · Verdict: Undervalued

The Verdict on COLL

COLLEGIUM PHARMACEUTICAL INC (COLL) appears Fairly Valued at its current market price of $33.27, according to our Monte Carlo simulations. Our analysis indicates a median fair value (P50) of $40.58, suggesting a potential +22.0% upside from the current level. While this implies some runway, the stock is considered balanced within our valuation framework, reflecting the complex interplay of fundamental drivers and probabilistic outcomes over thousands of forward scenarios. Investors should note this assessment when considering new positions or evaluating existing holdings in COLL.

How COLL stacks up against peers

Despite the lack of a specified sector for direct peer comparison, COLLEGIUM PHARMACEUTICAL INC maintains a strong quality tier, reflecting robust operational and financial health. This fundamental strength underpins the confidence in our median fair value of $40.58. The Monte Carlo simulation, by accounting for various revenue growth, margin, and discount rate scenarios, provides a comprehensive probabilistic valuation that helps contextualize the $33.27 relative to its inherent business quality. A strong quality tier typically signals resilience, which can be a key factor in mitigating downside scenarios in volatile markets, even at a fairly valued price point.

What this means for investors

For investors, COLL's current valuation at $33.27, closely aligned with its median fair value of $40.58 and offering +22.0% potential, suggests that the market is largely reflecting COLLEGIUM PHARMACEUTICAL INC's intrinsic value. While the Monte Carlo simulations do identify a range of possible outcomes, the P50 point is our central estimate of fair value. To explore the full probability distribution, including the bear (P10) and bull (P90) cases, and to track how COLL's fair value evolves with new data, sign up for a free FairCurve account.